SCHEMBL3485753

SCHEMBL3485753

Cc1ccc(S(=O)(=O)/N=c2\ccc(Cl)cn2CC(N)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.56
POLB P06746 1/20 0.45
PRSS1 P07477 5/20 0.41
F2 P00734 4/20 0.41
PRSS2 P07478 4/20 0.41
PRSS3 P35030 4/20 0.41
ALDH1A1 P00352 5/20 0.40
MAPT P10636 2/20 0.40
KMT2A Q03164 3/20 0.39
NPC1 O15118 2/20 0.38
CYP3A4 P08684 1/20 0.37
LMNA P02545 1/20 0.37
ACR P10323 1/20 0.36
EGFR P00533 1/20 0.36
ERBB2 P04626 1/20 0.36
DDAH1 O94760 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485754 1.00 PKM (0.56) PKMPOLBPRSS1F2PRSS2
SCHEMBL3486085 0.90 POLB (0.47) PKMPOLBPRSS1F2PRSS2
SCHEMBL3486084 0.90 POLB (0.47) PKMPOLBPRSS1F2PRSS2
SCHEMBL13498732 0.90 POLB (0.47) PKMPOLBPRSS1F2PRSS2
SCHEMBL3451435 0.85 POLB (0.45) PKMPOLBPRSS1F2PRSS2
SCHEMBL1302993 0.85 POLB (0.45) PKMPOLBPRSS1F2PRSS2
SCHEMBL1321460 0.85 POLB (0.45) PKMPOLBPRSS1F2PRSS2
SCHEMBL3486711 0.85 POLB (0.45) PKMPOLBPRSS1F2PRSS2
SCHEMBL1321457 0.85 POLB (0.45) PKMPOLBPRSS1F2PRSS2
SCHEMBL12119821 0.85 POLB (0.45) PKMPOLBPRSS1F2PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) 2010-02-04 US disclosed
EP-2058309-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-05-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029619-A1 FUSED HETEROCYCLIC COMPOUND IRAK1, IL1R1, IRAK2 PKM 1216/4885POLB 4619/4885PRSS1 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.